Oral peptide icotrokinra beats placebo in phase 2b ulcerative colitis trial
All three doses topped placebo at week 12, with 63% clinical response on 400 mg versus 27% on placebo among 252 patients.
PR
By Priya Raman · Science Reporter
Oct 15 02:20 ETSource: OC Academy
The wire
- 01The phase 2b ANTHEM-UC trial randomized 252 adults with moderately to severely active ulcerative colitis to once-daily oral icotrokinra 100 mg, 200 mg, 400 mg or placebo; week-12 clinical response reached 63%, 58% and 55% versus 27%.
- 02Icotrokinra is an oral peptide blocking the interleukin-23 receptor, offering an alternative to injected IL-23 monoclonals that require cold chain and parenteral administration.
- 03No unexpected safety signals emerged over 12 weeks, but the trial was mid-stage and short; phase 3 confirmation is still needed.
From the source
Read at ocacademy.inCan an Oral Peptide Transform Ulcerative Colitis Care?
Managing moderate to severe inflammatory bowel disease remains challenging for clinicians. Currently, biologic treatments targeting interleukin-23 require intravenous or subcutaneous administration. However, evaluating oral icotrokinra for ulcerative colitis offers an exciting new therapeutic avenue. This novel oral peptide selectively blocks interleukin-23 receptor signaling directly within the g
